Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

I-TECH (Lim)
 
NCT04920942
RCTivermectincontrolCOVID-19 mild to moderatesome concern
241/249 inconclusive
  • inconclusive 25 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
Abd-Elsalam
 
NCT04403555
RCTivermectincontrolCOVID-19 mild to moderatehigh
82/82 inconclusive
    Babalola RCTivermectinlopinavir/ritonavirCOVID-19 mild to moderatehigh
    21/20 no results
      Bukhari
       
      NCT04392713
      RCTivermectinstandard of careCOVID-19 mild to moderatehigh
      50/50 suggested
      • suggested 10.6-fold increase in viral clearance by day 7 but with a low degree of certainty due to high risk of bias
      Kirti
       
      CTRI/2020/08/027225
      RCTivermectinplaceboCOVID-19 mild to moderatesome concern
      57/58 inconclusive
      • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
      RIVET-COV (Mohan) (12mg and 24mg)
       
      CTRI/2020/06/026001
      RCTivermectinplaceboCOVID-19 mild to moderatehigh
      104/52 inconclusive
      • inconclusive 10 % increase in viral clearance ,viral clearance by day 7 (PE) but with a low degree of certainty due to high risk of bias
      Ahmed RCTivermectinplaceboCOVID-19 mild to moderatehigh
      48/24 suggested
      • suggested 3.1-fold increase in viral clearance (time to event analysis only),viral clearance by day 14 (PE) but with a low degree of certainty due to high risk of bias
      Paradoxically comparison of day 7 and 14 virological clearance between ivermectin doxycycline group vs placebo was not statistically significant (HR 2.3[0.6-9.0] and 1.7[0.8-4.0])
      Chaccour
       
      NCT04390022
      RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
      12/12 inconclusive
      • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
      Chachar
       
      NCT04739410
      RCTivermectinstandard of careCOVID-19 mild to moderatehigh
      25/25 inconclusive
      • inconclusive 19 % increase in clinical improvement,clinical improvement (7-day) (PE) but with a low degree of certainty due to high risk of bias
      Krolewiecki
       
      NCT004381884
      RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
      30/15 inconclusive
        NCT04523831 (Mahmud)
         
        NCT04523831
        RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
        200/200 safety concern
        • suggested 89 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 93 % increase in clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 56 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
        • statistically significant 17.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
        Shahbaznejad
         
        IRCT20111224008507N3
        RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
        35/38 inconclusive
          3 studies excluded by filtering options (0 RCT / 3 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).